



Patient Focused. Discovery Driven.

Exagen Inc. to Participate in Investor Summit Group's Q2 Conference

April 20, 2022

SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) --

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group's Q2 Conference, which takes place May 3rd - 4th, 2022, in New York City at the Westin New York Grand Central Hotel. Ron Rocca, Exagen's President and Chief Executive Officer, and Kamal Adawi, Exagen's Chief Financial Officer, will present on Wednesday, May 4th, at 2:00 PM ET. Interested parties may access the webcast of the presentation using a link on Exagen's website at <https://investors.exagen.com/events>.

About Exagen Inc.

Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand, several of which are based on our proprietary Cell-Bound Complement Activation Products, or CB-CAPs, technology. Exagen's goal is to enable providers to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including rheumatoid arthritis and lupus. For further information please visit www.exagen.com.

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen's business, including, without limitation: the COVID-19 pandemic may continue to adversely affect Exagen's business, financial condition and results of operations, including as a result of shutdowns of its facilities and operations as well as those of its suppliers and courier services, impeding patient movement and interruptions to healthcare services causing a decrease in test volumes, disruptions to the supply chain of material needed for its tests, its sales and commercialization activities and its ability to receive specimens and perform or deliver the results from its tests, delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen's commercial success depends upon attaining and maintaining significant market acceptance of its testing products and promoted therapeutics among rheumatologists, patients, third-party payors and others in the medical community; Exagen's ability to successfully execute on its business strategies; including its strategy of integrating the promotion of its existing and future proprietary testing products with the promotion of therapeutics; third party payors not providing coverage and adequate reimbursement for Exagen's testing products or promoted therapeutics; Exagen's ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen's business; and other risks described in Exagen's prior press releases and Exagen's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in Exagen's Annual Report on Form 10-K for the year ended December 31, 2021 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investor Relations

Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525

Company

Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514

Exagen®

Patient Focused. Discovery Driven.

Source: Exagen Inc.